Posted by Michael Wonder on 15 May 2019
Nivolumab and ipilimumab: drug combination has added benefit in advanced renal cell carcinoma
15 May 2019 - There are no serious disadvantages in terms of overall survival.
Renal cell carcinoma is one of the cancers in which the range of promising therapeutic options has widened considerably in recent years.
In its current review of nivolumab and ipilimumab, the Institute has come to a positive conclusion: patients with advanced renal cell carcinoma and a medium risk score, the drug combination offers a considerable added benefit. In those with at least three risk factors and an unfavourable prognosis, there is a significant additional benefit versus the ACT, sunitinib maleate.
